The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of
Single-dose pharmacokinetics and anticonvulsant efficacy of primidone in mice
β Scribed by Mr K. W. Leal; R. L. Rapport; A. J. Wilensky; P. N. Friel
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- English
- Weight
- 374 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The pharmacokinetics and efficacy of the anticonvulsant primidone (PRM) and its active metabolites, phenobarbital (PB) and phenylethylmalonamide (PEMA), were studied after singleβdose administration in mice. The halfβlife of PB is twice that of PRM and PEMA. The plasma/brain ratios provide evidence of poor penetration of PRM into brain. The results support our findings of negligible or absent PRM concentrations in the brains of patients on primidone therapy who were undergoing surgery for intractable epilepsy.
The anticonvulsant properties of PRM, PB, and PEMA against maximal electroshock in mice were also studied with the use of the metabolic inhibitor SKF 525A. The halfβlife, potency, peak anticonvulsant effect, and effective dose curves of these compounds indicate that the anticonvulsant effect of shortβterm oral PRM administration in mice is from derived PB.
π SIMILAR VOLUMES
The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.
The pharmacokinetics of a new serotonin 5-HT 2 antagonist, deramciclane, was studied. Single oral doses of 1, 3, 6 and 10 mg kg -1 and intravenous doses of 1, 3 and 6 mg kg -1 were administered in beagle dogs. Moreover, the steady state pharmacokinetics of 1, 3 and 6 mg kg -1 doses were studied. Der
The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg
Twenty-four healthy women received 2Β΄4 mg kg 71 dolasetron mesylate (1Β΄8 mg kg 71 dolasetron base) by a 10 min intravenous administration and by oral administration. Pharmacokinetics of dolasetron and of its active reduced metabolite MDL 74 156 were monitored for 48 h in plasma. Urine was collected